Gross margin % of 10x Genomics Inc Class A – HAN:1KJ
The article presents the gross margin percentage for 10x Genomics Inc Class A, traded on the Hannover Stock Exchange under the ticker 1KJ. It indicates that the market is currently closed with no trades recorded. The content is primarily a financial data point from TradingView.
Return on assets % of 10x Genomics Inc Class A – HAN:1KJ
The article provides financial data specifically focusing on the "Return on assets %" for 10x Genomics Inc Class A (HAN:1KJ), traded on the Hannover Stock Exchange. It indicates that the market is closed with no recent trades. The page is primarily a financial data point within a larger trading platform.
10x genomics director Shehnaaz Suliman sells $464,667 in stock
Shehnaaz Suliman, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 5,723 shares of company stock for approximately $464,667 on September 22, 2026, under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, despite InvestingPro analysis suggesting it is overvalued. The company recently reported a 3% revenue increase for Q2 2026 and an adjusted loss per share of $0.14, outperforming analyst expectations, though future prospects are viewed with a mix of optimism and caution due to the transition to the new Atera platform.
At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan.
10x Genomics, Inc. (TXG) CEO Serge Saxonov sold a total of 25,000 Class A common shares across five direct transactions on September 22, 2026. These sales were executed under a Rule 10b5-1 trading plan adopted in November 2025, with weighted-average sale prices ranging from $78.2284 to $82.3650 per share. Following these transactions, Saxonov's direct holdings amount to 1,050,249 Class A Common Stock shares, with additional indirect holdings through various trusts.
10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com
Shehnaaz Suliman, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 5,723 shares of the company's stock for approximately $464,667 on September 22, 2026, under a Rule 10b5-1 trading plan. The sale occurred as the stock trades near its 52-week high after a significant surge. Despite recent positive financial results, the stock is considered overvalued by InvestingPro analysis, with mixed analyst views on its future prospects.
Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions.
10x Genomics, Inc. director Suliman Shehnaaz sold a total of 5,723 shares of Class A Common Stock across five separate transactions on September 22, 2026. These sales were conducted under a Rule 10b5-1 trading plan established on March 13, 2026. The shares were sold at weighted average prices ranging from $78.1959 to $82.2768 per share.
5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale
An affiliate of 10x Genomics (NASDAQ: TXG), Shehnaaz Suliman, plans to sell 5,723 shares of Class A common stock under Rule 144, valued at approximately $452,689.20. The shares were acquired through RSU awards vesting between August 2024 and May 2025. J.P. Morgan Securities LLC will act as the broker for this sale, and a previous sale of the same number of shares by Suliman occurred on August 24, 2026, generating $140,477.91.
Price to earnings forward of 10x Genomics Inc Class A – LS:A2PPQJ
This article displays the "Price to earnings forward" for 10x Genomics Inc Class A (LS:A2PPQJ) on TradingView. It shows that the market is closed with no trades and provides an overview of financial data. The content is primarily a data point display from a financial platform.
10x genomics CFO Adam Taich disposes of $2.99 million in company stock By Investing.com
Adam Taich, CFO of 10x Genomics, Inc. (NASDAQ:TXG), sold approximately $2.99 million worth of company stock on September 9, 2026, under a Rule 10b5-1 trading plan. This transaction involved 46,388 shares sold at prices between $63.67 and $65.875, occurring as TXG stock neared its 52-week high after a significant 408% gain. Following the sale, Taich retains 316,344 shares, while the company recently reported strong Q2 2026 results surpassing analyst expectations, despite investor concerns about the Atera platform transition.
10x genomics CFO Adam Taich disposes of $2.99 million in company stock
Adam Taich, CFO of 10x Genomics, Inc. (NASDAQ:TXG), sold approximately $2.99 million worth of company stock on September 9, 2026, through a pre-arranged trading plan. This sale occurred as TXG stock was trading near its 52-week high after a significant 408% gain over the past year. Despite recent positive Q2 2026 earnings, analysts have mixed sentiments due to the company's transition to a new platform.
10x Genomics (TXG) director offloads 20,000 shares in open-market trades
John R. Stuelpnagel, a director at 10x Genomics (TXG), sold 20,000 shares of Class A common stock on September 3, 2026, in open-market transactions. The shares were sold in three blocks at weighted average prices ranging from $60.66 to $62.61, totaling approximately $1.24 million. This transaction was not conducted under a Rule 10b5-1 trading plan.
10x Genomics (TXG) CFO sells shares under preset trading plan
10x Genomics (TXG) Chief Financial Officer, Adam Taich, sold a total of 46,388 shares of Class A Common Stock on September 9, 2026. The sales occurred in three open-market transactions at weighted average prices ranging from approximately $63.68 to $65.26, executed under a Rule 10b5-1 trading plan adopted on June 10, 2026. After these transactions, Adam Taich directly holds 316,344 shares of Class A Common Stock.
T. Rowe Price reports 10%+ holding in 10x Genomics (TXG)
T. Rowe Price Associates, Inc. has disclosed an 11.7% beneficial ownership stake in 10x Genomics, Inc. (TXG), according to a Schedule 13G SEC filing. This amounts to 14,044,020 shares of Class A common stock, with T. Rowe Price asserting sole voting power over 13,511,751 shares and sole dispositive power over all 14,044,020 shares. Despite the disclosure, T. Rowe Price denies admission of beneficial ownership, stating the shares were acquired in the ordinary course of business and not for influencing control.
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 20,000 shares of the company's Class A Common Stock for approximately $1.2 million on September 3, 2026. This insider sale occurs as TXG stock trades near its 52-week high after a significant 386% return over the past year. Despite recent positive financial results, including exceeding revenue expectations, the company is navigating a transition to its new Atera platform, with analysts maintaining a positive outlook.
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com
John R. Stuelpnagel, a director at 10x Genomics Inc., sold approximately $1.2 million worth of company shares on September 3, 2026. This sale comes as the stock is near its 52-week high and is considered overvalued by InvestingPro analysis, despite recent positive Q2 2026 financial results and analyst optimism about its new Atera platform.
10x genomics director Stuelpnagel sells $1.2 million in shares
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 20,000 shares of the company's Class A Common Stock for approximately $1.2 million on September 3, 2026. This insider sale occurred as TXG stock trades near its 52-week high, with InvestingPro analysis suggesting the stock is overvalued despite positive recent financial results and analyst ratings. The company recently surpassed Q2 2026 revenue expectations but faces a softer near-term outlook due to its transition to the new Atera platform.
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold over $1.2 million worth of shares on September 3, 2026. This insider sale occurred while TXG stock is trading near its 52-week high and is considered overvalued by InvestingPro analysis, despite analysts predicting a return to profitability this year. The company recently surpassed Q2 2026 revenue expectations but faces a softer near-term outlook with its transition to the Atera platform.
10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan
10x Genomics (TXG) CEO Serge Saxonov sold a total of 10,486 shares of Class A Common Stock on August 26, 2026, as part of a Rule 10b5-1 trading plan adopted in November 2025. The sales were executed in multiple transactions at weighted average prices ranging from approximately $62.53 to $64.99 per share. Saxonov also maintains indirect holdings of Class A shares through three trusts where he serves as trustee.
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift
10x Genomics (TXG) CEO Serge Saxonov reported a bona fide gift of 100 Class A shares on September 1, 2026, with a reported price of $0.00 per share. Following this transaction, Saxonov directly holds 1,075,249 Class A shares and also maintains indirect ownership through various trusts. No Rule 10b5-1 trading plan was associated with this gift.
10x Genomics CEO Serge Saxonov sells $667,900 in stock
Serge Saxonov, CEO of 10x Genomics (NASDAQ:TXG), sold 10,486 shares of Class A Common Stock worth approximately $667,900 on August 26, 2026, pursuant to a pre-arranged trading plan. This sale occurred as TXG shares were near a 52-week high, despite the company recently exceeding Q2 2026 revenue and adjusted EPS expectations. Analysts have maintained a Buy rating on TXG, increasing price targets due to potential growth in AI and biopharma sectors.
10x Genomics CEO Serge Saxonov sells $667,900 in stock By Investing.com
10x Genomics CEO Serge Saxonov sold 10,486 shares of Class A Common Stock worth approximately $667,900 on August 26, 2026, executed under a Rule 10b5-1 trading plan. The sale occurred as the company's shares traded near their 52-week high, despite the stock appearing overvalued according to InvestingPro analysis. Saxonov still retains significant direct and indirect ownership in the company.
10x Genomics President Benjamin J. Hindson Sells Shares to Meet Tax Withholding Requirements
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 13,818 shares of Class A Common Stock on August 24, 2026. This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, Hindson retains beneficial ownership of 488,182 Class A Common Stock shares.
10x Genomics CEO Serge Saxonov Sells 18,545 Shares to Cover RSU Tax Withholding
Serge Saxonov, CEO and Director of 10x Genomics, Inc., sold 18,545 shares of Class A Common Stock on August 24, 2026. This transaction was executed to fulfill tax withholding obligations stemming from the vesting of restricted stock units. Post-sale, Saxonov directly holds 1,085,835 Class A Common Stock shares, with additional indirect holdings through various trusts.
10x Genomics (NASDAQ: TXG) holder to sell 2,207 RSU shares
Shehnaaz Suliman, a holder of 10x Genomics (NASDAQ: TXG), plans to sell 2,207 shares of Class A common stock acquired through RSU vesting, with J.P. Morgan Securities LLC handling the sale. The aggregate market value of these shares is $143,719.84. This Form 144 filing also notes Suliman previously sold 5,723 shares for $186,756.21 within the last three months.
10x Genomics (TXG) CEO gifts 4,000 shares in stock donation
10x Genomics, Inc. CEO Serge Saxonov reported a bona fide gift of 4,000 shares of Class A Common Stock on August 20, 2026. After this transaction, he directly holds 1,104,380 Class A shares and has indirect holdings through several family trusts where he serves as trustee. The gift was made without expectation of repayment and was not part of a Rule 10b5-1 trading plan.
Price to sales forward of 10x Genomics Inc Class A – MUN:1KJ
This page provides financial information for 10x Genomics Inc Class A (MUN:1KJ) on the Munich Stock Exchange, specifically focusing on its forward price-to-sales ratio. The content is primarily a navigation and information hub, indicating the stock market status and various available financial tools and data provided by TradingView and its partners.
ETFs Investing in 10x Genomics Inc Class A Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks, organized by market value. It details various ETFs, including their issuers, management styles, expense ratios, AUM, price changes, and 3-year NAV total returns, offering investors a broad overview of investment options for this stock.
10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan
10x Genomics (NASDAQ: TXG) director Sarah A. Teichmann reported two open-market sales of Class A Common Stock, totaling 7,551 shares. These transactions, executed on August 13 and August 14, 2026, were conducted under a Rule 10b5-1 trading plan adopted on May 14, 2026. The sales amounted to approximately $432,000, leaving Teichmann with 28,058 shares of Class A Common Stock.
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics
ARK Investment Management LLC and its CEO, Catherine D. Wood, have reported a beneficial ownership of 10,003,058 shares of 10x Genomics, Inc. Class A common stock as of June 30, 2026. This position represents an 8.56% stake in the company's outstanding Class A shares. The filing details the sole and shared voting and dispositive powers held by ARK and Wood over these shares.
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing
John R. Stuelpnagel, a Director at 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales were conducted in two open-market transactions, with 17,000 shares sold at a weighted average price of $57.5812 and 3,000 shares sold at $58.725. Following these transactions, Stuelpnagel's direct beneficial ownership in the company stands at 348,436 shares.
10x Genomics (TXG) director John Stuelpnagel sells 20,000 shares in August 11 trades
John R. Stuelpnagel, a director at 10x Genomics (TXG), sold a total of 20,000 Class A Common Stock shares on August 11, 2026. The sales were executed in two transactions: 17,000 shares at a weighted average price of $57.5812, and an additional 3,000 shares at $58.7250. This insider activity indicates a net sale of shares by a company director.
10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.com
John R. Stuelpnagel, a director at 10x Genomics, Inc. (NASDAQ:TXG), sold over $1.15 million worth of Class A Common Stock on August 11, 2026, selling 20,000 shares at prices between $57.5812 and $58.725. This sale occurred as TXG stock is near its 52-week high after a significant 339% gain over the past year, with Stuelpnagel still beneficially owning 348,436 shares. Despite the company surpassing Q2 2026 revenue expectations, the stock's valuation appears overvalued according to InvestingPro, and Canaccord Genuity recently raised its price target to $60 with a Buy rating.
10x Genomics, Inc. SEC Filing (Aug 11, 2026)
This article reports on an SEC Form 144 filing by 10x Genomics, Inc. (TXG) dated August 11, 2026. The filing indicates a proposed sale of 20,000 shares of Class A common stock by a filer, with an aggregate market value of $1,155,032.36, through Wells Fargo Clearing Services on Nasdaq. The shares were originally granted as founder shares on August 21, 2017.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are expressing bullish sentiments on several healthcare stocks, specifically Elanco Animal Health (ELAN), Zimmer Biomet Holdings (ZBH), and 10x Genomics (TXG). Analysts from Piper Sandler and Canaccord Genuity have reiterated Buy ratings for these companies, setting price targets that suggest significant upside from current levels. The article highlights analyst consensus and individual analyst performance for each stock.
10x Genomics (TXG): Doubled, Then Doubled Again
10x Genomics (TXG) has been a significant winner for Hedgeye, with its stock price soaring over 157% since May 19 due to strong Signal Strength, favorable macroeconomic "Quads," and robust fundamental performance. The company recently reported strong second-quarter results, raised full-year guidance, and despite a tactical sale by CEO Keith McCullough for a 20% gain, it remains a "Best Idea Long" for Hedgeye's Health Care team. The success is attributed to the firm's comprehensive investment process, including academic grant cycle analysis for new lab technologies like spatial genomics, which is experiencing high demand.
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG
This article provides financial information for 10x Genomics Inc Class A (BMV:TXG) on TradingView. It specifically highlights the company's enterprise value to EBIT forward metric. The content appears to be a stub or a placeholder page within a larger financial data platform.
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX)
Analysts have issued neutral "Hold" ratings for three healthcare companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG), and Teleflex (TFX). Bank of America Securities analysts Tazeen Ahmad, Michael Ryskin, and Travis Steed maintained Hold ratings for each respective company, citing various factors including stock performance relative to 52-week lows and updated price targets from other firms. While consensus for all three is a "Moderate Buy," price targets suggest varying upsides or downsides from current levels.
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash
10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by increases in consumables and services. The company ended the quarter with $502.5M in cash and cash equivalents and acquired Proteintech Genomics for $6.1M to expand its proteomics capabilities.
10x Genomics, Inc. (TXG) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of 10x Genomics, Inc. (TXG), including its current stock price, recent news, chart performance over various periods, and key financial data. The article details the company's products and services, such as the Chromium and Visium platforms and Xenium Analyzer, which are used for analyzing biological systems. It also presents analyst insights, earnings trends, and performance comparisons against benchmarks like the S&P 500.
10x Genomics, CHUV Expect Hundreds of Patients in Cancer Study
10x Genomics announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study aims to identify clinically relevant biomarkers for predicting treatment response and prognosis across various solid tumors using 10x's Flex Apex and Xenium platforms, with plans to include hundreds of patients. This collaboration seeks to integrate single cell and spatial biology with clinical outcomes to improve personalized treatment strategies.
10x Genomics Inc Class A Revenue Breakdown – GETTEX:1KJ
This article details the revenue breakdown for 10x Genomics Inc Class A (GETTEX:1KJ). In the last fiscal year, the company generated 547.31 million EUR, with the Consumables - Single Cell segment contributing the most at 309.24 million EUR. The United States was the largest regional contributor, accounting for 295.03 million EUR of the revenue.
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
Shares of Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics all traded down after concerns arose over a rising number of uninsured patients, a trend highlighted in HCA Healthcare's recent earnings report. The "negative payer mix shift" could lead to more uncompensated care and squeeze profit margins for healthcare providers. Hims & Hers Health, despite its recent decline, has shown significant returns for long-term investors and recently partnered with Novo Nordisk for GLP-1 drug sales.
ETFs Investing in 10x Genomics Inc Class A Stocks
This article lists the various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A (TXG) stocks. It provides a detailed table including fund names, market value of TXG holdings, weight in the fund, issuer, management style, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return for each ETF. The information helps investors identify funds offering exposure to 10x Genomics Inc.
TXG Stock Rallies As Wall Street Hikes Price Targets
10x Genomics Inc. (TXG) stock has rallied by 9.43% due to strong demand for its single-cell platform and increased price targets from Wall Street analysts. Barclays, Morgan Stanley, and Citi have all raised their price targets for TXG, indicating improved sentiment for life science tools and the company's strategic collaboration with Cleveland Clinic for advanced bladder cancer research. Despite a recent insider sale by CEO Serge Saxonov, the stock's momentum is driven by fundamental growth, positive cash flow, and bullish analyst calls.
TXG Stock Climbs As Wall Street Hikes Price Targets
10x Genomics Inc. (TXG) stock has surged over 12% following positive analyst coverage and strategic company developments. Barclays and Citi both raised their price targets for TXG, citing improving sentiment in life science tools and the potential for earnings growth. Key drivers include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic for advanced cancer research, despite a recent insider stock sale.
Price to sales forward of 10x Genomics Inc Class A – SWB:1KJ
This article provides the forward price-to-sales ratio for 10x Genomics Inc Class A (SWB:1KJ) listed on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content emphasizes financial data and market specifics for this biotechnology company.
ETFs Investing in 10x Genomics Inc Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks. It provides detailed financial information for each ETF, including market value, weight of the stock in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and NAV total return over three years. The ETFs are primarily focused on themes like innovation, genomics, small-cap, and health technology.
1KJ Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analyst opinions. It includes details on price estimates, historical highs and lows, upcoming earnings reports, and financial metrics such as EPS, revenue, net income, and EBITDA. The content also addresses frequently asked questions about the company's stock.
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response
10x Genomics has announced a multi-year research collaboration with Cleveland Clinic to develop advanced diagnostic applications for bladder cancer. The study will utilize 10x Genomics' Flex Apex, Xenium, and later Atera platforms to analyze bladder cancer tumor samples. The primary goal is to identify biomarkers that can predict patient responses to antibody-drug conjugates and immunotherapies, ultimately aiding in personalized treatment decisions and future diagnostic development.
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)
This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA. The article also provides guidance on how to buy 1KJ stocks through online brokers.
